Kenvue Inc.
Every calculator, already run for KVUE
Open the full toolkit →You have the numbers on KVUE. Get the argument.
A written report on which of these readings actually decide the outcome for Kenvue Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering KVUEAnalyst Price Target Disagreement for Kenvue Inc.
Wall Street's bull case implies +20% from the current price; the bear case implies -6%. Analysts are relatively aligned on KVUE's range.
Ownership & short interest
About Kenvue Inc.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products…
KVUE — frequently asked
Is KVUE a buy right now?
Wall Street's consensus rating on Kenvue Inc. is Hold across 14 analysts, with a mean price target of $19.50 (+2% vs. the current $19.20). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is KVUE overvalued?
KVUE trades at 22.6x trailing earnings, against a DCF fair value of $39 per share. The current price implies -2% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is KVUE's next earnings date?
Kenvue Inc. is next scheduled to report earnings around Nov 5, 2026. A full KVUE research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Kenvue Inc.?
Analysts covering Kenvue Inc. (KVUE) range from a bear-case target of $18.00 to a bull-case high of $23.00, with a mean consensus target of $19.50 across 12 analysts. The spread of $5.00 (26% of the current price) indicates moderate disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Kenvue Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Kenvue Inc.
Start with the evergreen guides that matter most for Consumer Defensive, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full KVUE research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Kenvue Inc., in minutes. 3 free reports included with every account — no credit card required.